Accretion Pharmaceuticals
Accretion Pharmaceuticals (ACCPL) share price was ₹185.00 at the 28 Oct 2026 close; market capitalisation ₹206 Cr; sector Healthcare. The share price rose 214.1% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue rose 18.2% year on year to ₹45.89 Cr and net profit rose 13.6% year on year to ₹4.92 Cr (compared with Mar 2025). Promoters held 73.52% of Accretion Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 28 Oct 2026, 14:52 IST · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,765.90 | 35.03 | 4,23,699 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,653.50 | 87.62 | 2,56,270 Cr | 15.29 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.20 | 72.14 | 1,74,787 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,190.10 | 108.21 | 1,18,334 Cr | 22.33 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.60 | 26.29 | 1,17,865 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,337.30 | 34.64 | 1,11,622 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,363.10 | 32.66 | 1,10,119 Cr | 3.11 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Accretion Pharmaceuticals (this company) | ₹185.00 | — | 206 Cr | 3.76 | 0.00% | 17.67% | 24.99% | — | — |
| Median 8 companies | ₹1,564.50 | 35.03 | 1,18,099 Cr | 4.71 | 0.47% | 14.56% | 18.45% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 81/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
Technical Indicators
Oscillators
Bearish
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year Operating margin 17.17% · Mar 2026
Quarterly Results
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 13.35 | 18.56 | 38.81 | 43.74 | 45.89 |
| Expenses | 10.78 | 14.23 | 31.27 | 36.67 | 38.01 |
| Operating Profit | 2.57 | 4.33 | 7.54 | 7.07 | 7.88 |
| OPM % | 19.25% | 23.33% | 19.43% | 16.16% | 17.17% |
| Other Income | 0.05 | 0.02 | 0.08 | 0.11 | 0.08 |
| Interest | 0.4 | 0.69 | 0.74 | 0.37 | 0.48 |
| Depreciation | 0.22 | 0.37 | 0.41 | 0.4 | 0.81 |
| PBT | 2 | 3.29 | 6.47 | 6.41 | 6.67 |
| Tax % | 25% | 25.23% | 33.08% | 25.9% | 26.24% |
| Net Profit | 1.49 | 2.46 | 4.33 | 4.75 | 4.92 |
| EPS (₹) | 1.96 | 3.01 | 5.3 | 4.27 | 4.43 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 13.35 | 57.38 | 89.63 |
| Expenses | 10.78 | 45.49 | 74.66 |
| Operating Profit | 2.57 | 11.89 | 14.97 |
| OPM % | 19.25% | 20.72% | 16.7% |
| Other Income | 0.05 | 0.09 | 0.19 |
| Interest | 0.4 | 1.44 | 0.87 |
| Depreciation | 0.22 | 0.77 | 1.21 |
| PBT | 2 | 9.77 | 13.08 |
| Tax % | 25% | 30.4% | 26.15% |
| Net Profit | 1.49 | 6.79 | 9.67 |
| EPS (₹) | 1.96 | 8.31 | 8.7 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 4 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 43.59 |
| Borrowings | 13.48 | 14.1 | 12.32 |
| Other Liabilities | 8.47 | 10.48 | 9.65 |
| Total Liabilities | 27.44 | 39.87 | 76.68 |
| Fixed Assets | 5.25 | 6.09 | 13.21 |
| CWIP | 0 | 0 | 0.2 |
| Investments | 0 | 0 | 0 |
| Other Assets | 22.19 | 33.78 | 63.27 |
| Total Assets | 27.44 | 39.87 | 76.68 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | -11.51 | -0.62 | -14.53 |
| Investing | -5.48 | -1.61 | -8.53 |
| Financing | 17.08 | 2.19 | 27.04 |
| Net Cash Flow | 0.09 | -0.04 | 3.97 |
| Free Cash Flow | -16.99 | -2.23 | -23.06 |
| CFO/EBITDA | -479 | 18 | -75 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 159 | 74.17 | 91.22 |
| Inventory Days | 564 | 188 | 159 |
| Days Payable | 256 | 69.41 | 32.32 |
| Cash Conversion Cycle | 466 | 193 | 218 |
| Working Capital Days | 189 | 64.69 | 145 |
| ROCE % | — | 46.36% | 28.94% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Accretion Pharmaceuticals insights
57 extracted metrics + investor summaries across FY22–FY26.
Documents
Frequently Asked Questions about Accretion Pharmaceuticals
What does Accretion Pharmaceuticals Ltd do?
Where is Accretion Pharmaceuticals Ltd (ACCPL) listed?
Which sector does Accretion Pharmaceuticals Ltd belong to?
What is the market capitalisation of Accretion Pharmaceuticals Ltd?
What is the 52-week high and low of Accretion Pharmaceuticals Ltd?
What is the Return on Equity (ROE) of Accretion Pharmaceuticals Ltd?
Company Information
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACCPL.md for Accretion Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.